The Latest Articles from Streetwise Reports


Analyst Upgrade Ignites Duchenne's Muscular Dystrophy Research Firm's Shares

  ()
Solid Biosciences' shares are up by more than 40% after Chardan Capital Markets upgraded the firm's shares from "neutral" to "buy" and raised its price target from $7.50 to $10.00/share. read more >

InMode Reports Solid Q2 Earnings and Appoints Paula Abdul as Brand Ambassador

  ()
InMode Ltd. reported Q2/19 earnings and announced that international pop superstar Paula Abdul will be its brand ambassador sending shares "Straight Up" 15% as investors "Rush Rush" to purchase shares today. read more >

Deciphera's Shares Open 115% Higher on Phase 3 Ripretinib Results

  ()
Deciphera Pharmaceuticals announced positive top-line results from the INVICTUS pivotal phase 3 clinical study of ripretinib in patients with advanced gastrointestinal stromal tumors. read more >

Amgen Shares React Favorably to Enbrel Patent Case Victory

  ()
Amgen shares traded 56% higher on news that the company has won its Enbrel (etanercept) patent court case. read more >

Biotech's DMD Therapeutic 'Solidifies the Ground for Potential Pivotal Design'

Research Report
  ()
The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report. read more >

Puma Biotech Shares Up More Than 20% on Q2 Earnings and Breast Cancer Drug Sales

  ()
Shares in Puma Biotechnology traded 20% higher after the company released Q2/19 earnings and reported positive NERLYNX revenue growth. read more >

Avedro Shares Looking Up 35% with Glaukos Merger

  ()
Avedro Inc. and Glaukos Corp. announced that the firms' boards of directors have executed a definitive merger agreement. The all-stock deal is expected to close in Q4/19. read more >

Guardant Health Reports Quarterly Revenue Up 178%

  ()
Guardant Health Inc. reported strong growth for Q2/19 versus the same period last year and raised its full-year 2019 revenue guidance to $180190 million. read more >

Allakos Shares Double on AK002 Phase 2 Results and Earnings

  ()
Allakos Inc. shares soared as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. read more >

Biotech 'Thinking Several Steps Ahead with Optimizing IVR Quality Control'

Research Report
  ()
The company's latest science, presented at a recent conference, is discussed in a ROTH Capital Partners report. read more >

Biotech's Mosquito Test 'Gains Market Acceptance'

Research Report
  ()
This West Nile virus test and others including cancer diagnostic tests in the Utah company's pipeline are discussed in an H.C. Wainwright & Co. report. read more >

Tandem Increases Unit Sales of t:slim X2 Insulin Pumps 290% Worldwide

  ()
Tandem Diabetes Care's second quarter earnings highlighted a 290% increase in unit sales of its t:slim X2 insulin pumps that feature integrated continuous glucose monitoring and remote software update capability. read more >

Gaia Grow Corp. Plants 1,494 Acres of Hemp in Canada and Plans First Harvest in 2 Months

Contributed Opinion
  ()
Gaia Grow Corp. CEO Frederick Pels speaks with Peter Epstein of Epstein Research on the day his company begins trading on the TSX Venture Exchange. read more >

Led by Sales of HETLIOZ, Vanda Increases Quarterly Revenues by 25%

  ()
Shares of Vanda Pharmaceuticals traded nearly 30% higher after the company released Q2/19 earnings and positive sales trends for both HETLIOZ and Fanapt. read more >

EMA Opinion Bodes Well for Biopharma's Drug Getting Orphan Status

Research Report
  ()
The designation, opinion and asset are discussed in a ROTH Capital Partners report. read more >
News Update

Firm's Cannabis Flower Yield Surpasses Expectations

News Update
  ()
Also, the company begins growing a second strain. read more >

Mylan Gets a Shot in the Arm with Pfizer Merger Deal

  ()
EpiPen manufacturer Mylan N.V. announced that the company will merge with Pfizer Inc.'s Upjohn Division, which holds Pfizer's off-patent branded and generic drugs, forming a new company. read more >

Catasys: This Is Bigger Than You Think

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research examines the "blockbuster" implications of a recent announcement about this company's OnTrak program. read more >

eHealth Shares Up 25% as Quarterly Revenue Doubled and 2019 Guidance Raised

  ()
The prognosis for online exchange operator eHealth Inc. looks positive as the company reported a 101% increase in Q2/19 revenues over the prior year period and raised full year 2019 revenue estimates by $50 million to $365385 million, compared with previous guidance of $315335 million for 2019. read more >

Align Technology Reports Strong Q2 Growth but China Sales Worries Leave Investors Frowning

  ()
Orthodontic and GP Dental medical device maker Align Technology announced a 24.6% increase in sales volume of its Invisalign products in its Q2/19 earnings report, but investors are not smiling much over China growth concerns as the shares of the company have fallen more than 25%. read more >

Anixa Licenses Another Potential Blockbuster

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research discusses a major collaboration with the Cleveland Clinic for his top pick stock of the year. read more >

Edwards Lifesciences Gets a Charge on Positive Q2 Earnings Report

  ()
Edwards Lifesciences is trading higher after reporting higher than expected adjusted earnings for Q2/19. The company estimates that the FDA will approve its SAPIEN 3 valve and SAPIEN 3 Ultra system in Q3/19. read more >

Biotech Firm ''Creating Innovative Solutions' for Female Health

Research Report
  ()
The company's most advanced assets are discussed in a Dawson James Securities report. read more >

Biopharma's New License Agreement with Gilead 'Brings Strong Validation and Economics'

Research Report
  ()
The specifics and benefits of the deal are discussed in an H.C. Wainwright & Co. report. read more >

Interim Data Indicate Multiantigen Cell Therapy in Solid Tumors 'Just Might Work'

Research Report
  ()
The immuno-oncology company's findings are reviewed in a ROTH Capital Partners report. read more >
Showing Results: 1 to 25 of 140 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts